The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?
Open accessAbstract
In September 2012, a 74-year-old nonsmoker man was admitted to our hospital with dyspnea and general health degradation. A tumor in the upper lobe of the right lung, bilateral mediastinal lymphadenopathies, and a right pleural effusion were evident on abdominal computed tomography (CT) scan (Fig. 1B). Both pleural effusion and lung biopsies contained tumor cells presenting the p.L858R EGFR (exon 21) mutation. This alteration was also detected in the plasma sample collected before treatment (Fig.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“use of liquid biopsies from plasma to monitor tumor progression and identify EGFR mutations associated with resistance to therapy (e.g., acquired T790M) has been documented, with such biopsies showing 60–80% sensitivity and specificity approaching 100% in detecting specific resistance mutations.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,174
Yung, T., Chan, K. C. A., Mok, T. S. K., TONG, J. H. M., To, K., & Lo, Y. M. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2622 · Cited by 386
Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Negoro, S., Nishio, K., Itoh, Y., Jiang, H., Duffield, E. L., McCormack, R., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307f98 · Cited by 209
Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung Cancer
Bai, H., Wang, Z., Chen, K., Zhao, J., Lee, J. J., Wang, S., Zhou, Q., Zhuo, M., Mao, L., An, T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3744 · Cited by 199
Ilié, M., Long-Mira, É., Butori, C., Hofman, V., Coëlle, C., Mauro, V., Zahaf, K., Marquette, C., Mouroux, J., Paterlini-Bréchot, P., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds137 · Cited by 163
Vallée, A., Marcq, M., Bizieux, A., Kouri, C. E., Lacroix, H., Bennouna, J., Douillard, J., & Denis, M. G. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.014 · Cited by 85
Self-citationVallée, A., Loupp, A.-G. L., & Denis, M. G. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.11.014 · Cited by 55
Self-citationEGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients
Yam, I., Lam, D. C.-L., Chan, K., Ho, J., Ip, M., Lam, W. K., Chan, T., & Chan, V. W. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182558198 · Cited by 45
Flagged first, then by citations
Cited by
Sorted by citations
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115
Metadata
- Authors
- Marcq, M., Vallée, A., Bizieux, A., & Denis, M. G.
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Corresponding author
- Denis, Marc G.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 9
- Issue
- 7
- Pages
- e49-e50
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC4132039
- OpenAlex
- W2082376763
- Cited by
- 20
- References
- 10
- Citations by year
- 2020: 2 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 4 · 2015: 8 · 2014: 1
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- EGFR mutation, lung adenocarcinoma, plasma biomarkers, liquid biopsy, tyrosine kinase inhibitors, treatment response monitoring, pleural effusion, mediastinal lymphadenopathy
- MeSH terms
- Adenocarcinoma, Aged, DNA, Neoplasm, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Protein-Tyrosine Kinases, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
